Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?
Astria Therapeutics shares surged up to 50% on Oct. 14, 2025, after BioCryst Pharmaceuticals agreed to acquire the company in a cash-and-stock deal valuing ATXS at about $13 per share. Halper Sadeh LLC announced an investigation into the fairness of the sale. Astria’s lead drug navenibart is in Phase 3 trials for hereditary angioedema, with topline data expected in early 2027.
